Bristol-Myers Squibb 8-K: Financial Condition & Operations Update

Ticker: CELG-RI · Form: 8-K · Filed: Feb 2, 2024 · CIK: 14272

Bristol Myers Squibb Co 8-K Filing Summary
FieldDetail
CompanyBristol Myers Squibb Co (CELG-RI)
Form Type8-K
Filed DateFeb 2, 2024
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.10
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: financial-condition, debt, operations, regulation-fd

TL;DR

**BMS filed an 8-K on Feb 2, 2024, updating on financial condition, including debt and Celgene CVRs.**

AI Summary

Bristol-Myers Squibb Company filed an 8-K on February 2, 2024, to report on its financial condition and operations, specifically mentioning its Common Stock ($0.10 Par Value), 1.000% Notes due 2025, 1.750% Notes due 2035, and Celgene Contingent Value Rights. This filing indicates that the company is providing updated financial information, which is crucial for investors to assess the company's current health and future prospects, especially regarding its debt obligations and the performance of its Celgene acquisition.

Why It Matters

This filing provides a snapshot of Bristol-Myers Squibb's financial health, allowing investors to understand its current debt structure and the status of its Celgene acquisition, which can impact future stock performance.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial condition and operations, not indicating any immediate new risks or significant changes.

Analyst Insight

Investors should review the full financial statements and exhibits referenced in this 8-K to understand the detailed results of operations and financial condition, especially concerning the performance of Celgene Contingent Value Rights and the company's debt obligations.

Key Numbers

  • 2025 — Maturity Year (for 1.000% Notes)
  • 2035 — Maturity Year (for 1.750% Notes)
  • 0.10 — Par Value (per share of Common Stock)

Key Players & Entities

  • BRISTOL-MYERS SQUIBB COMPANY (company) — the registrant filing the 8-K
  • Celgene Contingent Value Rights (company) — a financial instrument related to the Celgene acquisition
  • $0.10 (dollar_amount) — par value of Common Stock
  • 1.000% (dollar_amount) — interest rate of Notes due 2025
  • 1.750% (dollar_amount) — interest rate of Notes due 2035
  • February 2, 2024 (date) — date of earliest event reported and filing date

FAQ

What is the purpose of Bristol-Myers Squibb Company's 8-K filing on February 2, 2024?

The purpose of the 8-K filing on February 2, 2024, is to report on the company's Results of Operations and Financial Condition, Regulation FD Disclosure, and Financial Statements and Exhibits, as indicated by the 'ITEM INFORMATION' sections.

What specific financial instruments are mentioned in this 8-K filing?

The filing specifically mentions 'bmy:CommonStock0.10ParValueMember', 'bmy:A1.000Notesdue2025Member', 'bmy:A1.750Notesdue2035Member', and 'bmy:CelgeneContingentValueRightsMember'.

What is the par value of Bristol-Myers Squibb's Common Stock as stated in the filing?

The par value of Bristol-Myers Squibb's Common Stock is stated as $0.10, identified as 'bmy:CommonStock0.10ParValueMember'.

When do the 1.000% Notes mentioned in the filing mature?

The 1.000% Notes mentioned in the filing are identified as 'bmy:A1.000Notesdue2025Member', indicating they are due in 2025.

What is the interest rate and maturity year for the other set of notes mentioned?

The other set of notes mentioned are 'bmy:A1.750Notesdue2035Member', which have an interest rate of 1.750% and are due in 2035.

Filing Stats: 877 words · 4 min read · ~3 pages · Grade level 9.9 · Accepted 2024-02-02 07:46:16

Key Financial Figures

  • $0.10 — ange on which registered Common Stock, $0.10 Par Value BMY New York Stock Exchange

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On February 2, 2024, Bristol-Myers Squibb Company (the "Company") issued a press release (the "Earnings Press Release") announcing its financial results for the fourth quarter of 2023 and full year of 2023. A copy of the Earnings Press Release is furnished pursuant to this Item 2.02 as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein in its entirety.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On February 2, 2024, the Company posted on its website at www.bms.com a presentation (the "Bristol Myers Presentation") on certain financial and operating initiatives available for viewing during the Company's conference call and webcast announcing its financial results for the fourth quarter of 2023 and full year of 2023 at 8:00 a.m. Eastern time. A copy of the Bristol Myers Presentation is furnished pursuant to this Item 7.01 as Exhibit 99.2 to this Current Report on Form 8-K and incorporated by reference herein in its entirety. The Earnings Press Release and the Bristol Myers Presentation include references to non-GAAP financial information. Reconciliations between the non-GAAP financial measures and the comparable GAAP financial measures and the reasons for the presentation of such non-GAAP financial measures, are available in the Earnings Press Release which is included as Exhibit 99.1 hereto. The Bristol Myers Presentation should be read in conjunction with the Earnings Press Release. The Company reserves the right to discontinue availability of the Bristol Myers Presentation from its website at any time. Pursuant to General Instruction B.2. to Form 8-K, the information set forth in this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1, and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities thereof, nor shall it be incorporated by reference into future filings by the Company under the Exchange Act or under the Securities Act of 1933, as amended, except to the extent specifically provided in any such filing. Additionally, the submission of the information set forth in this Item 7.01 is not deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely by Regulation FD.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are furnished as part of this Current Report on Form 8-K: Exhibit No. Description 99.1 Press release of Bristol-Myers Squibb Company dated February 2, 2024. 99.2 Presentation Materials of Bristol-Myers Squibb Company dated February 2, 2024 . 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). EXHIBIT INDEX Exhibit No. Description 99.1 Press release of Bristol-Myers Squibb Company dated February 2, 2024 99.2 Presentation Materials of Bristol-Myers Squibb Company dated February 2, 2024 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRISTOL-MYERS SQUIBB COMPANY Dated: February 2, 2024 By: /s/ Kimberly M. Jablonski Name: Kimberly M. Jablonski Title: Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.